OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The business, which has been renamed Woodstock Sterile Solutions, will operate out of a single site in Woodstock, IL, and will support clinical- to commercial-stage formulation and manufacturing.
SK Capital Partners, a private investment firm focused on the specialty materials, chemicals, and pharmaceuticals sectors, announced on March 31, 2021 it has completed its acquisition of Catalent’s blow-fill-seal (BFS) sterile contract development and manufacturing organization (CDMO).
The business, which has been renamed Woodstock Sterile Solutions, will operate out of a single site in Woodstock, IL, and will support clinical to commercial stage formulation and manufacturing, SK Capital said in a company press release. The company will also focus on BFS sterile manufacturing and formulation for complex chemistries, including small molecules, biologics, macromolecules, and potent compounds.
Woodstock has appointed Paul Josephs as CEO, according to the press release. Most recently, Josephs served as the head of Contract Development and Manufacturing and Global Business Development at Mylan.
“We are excited to launch Woodstock Sterile Solutions as an independent company, building on its decades of experience in serving commercial and development customers,” said Aaron Davenport, managing director of SK Capital, in the press release. “We are delighted that Paul Josephs is joining to lead the very capable Woodstock team. Paul is a CDMO industry veteran who brings sterile production experience and contemporary leadership skills to ensure an environment committed to operational excellence, customer delight, innovation, and a partnership-driven approach for Woodstock’s customers, suppliers, and employees.”
“I am truly honored and excited to lead an organization with the heritage and potential of Woodstock,” Josephs added in the press release. “I look forward to partnering with SK Capital, the executive team, and all Woodstock associates to leverage the company’s unique sterile manufacturing capabilities, strong market position, and exceptional talent to execute our growth strategy. The BFS and sterile manufacturing markets are significant growth areas in our industry and together we have a great opportunity to positively impact the lives of countless patients, domestically and abroad.”
Source: SK Capital